Shots: Boehringer Ingelheim has acquired Global Stem cell Technology (GST) focusing to strengthen its portfolio capabilities to accelerate innovation and growth The acquisition follows two years of partnership b/w the companies that brought the first-ever registered stem cell-based veterinary medicine (Arti-Cell Forte) in the EU The acquisition of GST will accelerate the development pipeline of […]Read More
Shots: Elanco has received the US FTC’s approval for its acquisition of Bayer Animal Health, representing the final antitrust clearance needed to complete the transaction, which continues track for closing at the beginning of August The FTC’s approval follows divestiture of global rights for Osurnia to treat otitis externa in dogs, US rights for Capstar […]Read More
Shots: The US FDA approves Bravecto 1-month (fluralaner) chews for dogs and puppies aged≥ 8 weeks. The approval will expand Merck’s parasiticide portfolio, which are extended duration flea and tick protection products offering parasite protection for dogs The product is suitable for dogs in the early stages of life to begin a regimen of monthly […]Read More
Shots: Boehringer’s Ingelvac CSF MLV has obtained a New Veterinary Drug Registration Certificate from the Ministry of Agriculture and Rural Affairs of China The vaccine is jointly developed by Boehringer and Chinese research institutes and will be produced at BI’s Taizhou plant, Jiangsu province, and is expected to be commercialized in H1’21 The vaccine is […]Read More
Shots: The EC has granted approval of Elanco’s pending acquisition of Bayer’s animal health business. The company continues to progress toward a mid-year closing, anticipated Aug 03, 2020 The EC’s approval follows the divestiture of global rights for Osurnia to treat otitis externa in dogs, WW rights of Vecoxa to prevent & treat coccidiosis in […]Read More
Shots: Merck Animal Health to acquire the US rights to Sentinel flavor tabs and chews in the companion animal category, under the agreement with Virbac. The transaction is expected to be closed by mid-2020 With the acquisition, Merck expects to provide veterinarians continuous parasite protection for dogs in easy to administer, palatable formulations The products […]Read More
Shots: Elanco acquires Bayer’s animal health business in cash & stock transaction, making a total deal value $7.6B. Bayer to get $5.32B cash as up front and $2.28B/~68M as Elanco’s common share with the expected closure of transaction in mid-2020 The focus of the acquisition is to strengthen & accelerating Elanco’s IPP strategy through a […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
